BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
月曜日, 9 28

Elicio Therapeutics Inc

ELTXNASDAQ
Trade with Public
Trade with Public
$1.84
-0.04-2.13%
近くで: Sep 24, 5:00 PM EST
$1.85
-0.025-1.33%
プレマーケット: 4:00 AM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Elicio Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elicio Therapeutics (ELTX).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

4Buy
1Hold
Consensus RatingBuy# Analysts5Avg. Consensus PT$15Upside to Avg. PT+699.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Sep 24, 2026B. Riley SecuritiesMayank MamtaniPT CutBuy$27→$8
Aug 18, 2026HC Wainwright & Co.Robert BurnsMaintainedBuy$23
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8

B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.
Benzinga Newsdesk

PRO
Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12

Ladenburg Thalmann analyst Kevin DeGeeter assumes Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

PRO
Jones Trading Downgrades Elicio Therapeutics to Hold

Jones Trading analyst Boris Peaker downgrades Elicio Therapeutics (NASDAQ:ELTX) from Buy to Hold.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $23

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price target from $17 to $23.
Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $27

B. Riley Securities analyst Mayank Mamtani initiates coverage on Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $27.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved